FDA warns of possible overdoses with compounded semaglutide injections

The Food and Drug Administration said it has received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products. Dosing errors have resulted from patients measuring and self-administering incorrect doses of the drug and health care providers miscalculating doses of the drug. Semaglutide is Novo Nordisk’s glucagon-like peptide-1 receptor agonist with three FDA-approved products: Wegovy injection, Ozempic injection and Rybelsus tablet. The FDA encourages health care providers and compounders to provide patients with the appropriate syringe size for the intended dose and counsel patients on how to measure the intended dose using the syringe. Shares of Hims & Hers (HIMS), which offers a compounded injectable weight loss drug with semaglutide, are down 2% to $22.73 in morning trading.